J10对普利多啶临床试验综合安全性数据的分析表明，在临床相关剂量为45mg / bid时，其安全性和耐受性良好

{"title":"J10对普利多啶临床试验综合安全性数据的分析表明，在临床相关剂量为45mg / bid时，其安全性和耐受性良好","authors":"M. Geva, B. Darpo, G. Ferber, Y. Paul Goldberg, R. Reilmann, M. R. Hayden","doi":"10.1136/jnnp-2022-ehdn.260","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":251913,"journal":{"name":"J: Clinical therapeutics","volume":"35 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"J10 Analysis of integrated safety data from pridopidine clinical trials demonstrates a favorable safety and tolerability profile at the clinically relevant dose of 45 mg bid\",\"authors\":\"M. Geva, B. Darpo, G. Ferber, Y. Paul Goldberg, R. Reilmann, M. R. Hayden\",\"doi\":\"10.1136/jnnp-2022-ehdn.260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":251913,\"journal\":{\"name\":\"J: Clinical therapeutics\",\"volume\":\"35 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"J: Clinical therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jnnp-2022-ehdn.260\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"J: Clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jnnp-2022-ehdn.260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}